[{"id":"38aa9c92-b86b-4c71-ac1f-a0585bd922fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05987696","created_at":"2023-08-14T15:10:11.648Z","updated_at":"2024-07-02T16:35:40.228Z","phase":"Phase 1","brief_title":"Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05987696","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive • CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • CD33/CLL1 dual CAR-NK cell • Super NK cell therapy"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-11"},{"id":"9bd42bb7-1fd2-4126-995e-0c74a47e0e47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05665075","created_at":"2022-12-27T15:59:02.163Z","updated_at":"2024-07-02T16:35:58.332Z","phase":"Phase 1","brief_title":"Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05665075","lead_sponsor":"Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • QN-023a"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 12/24/2022","start_date":" 12/24/2022","primary_txt":" Primary completion: 12/24/2023","primary_completion_date":" 12/24/2023","study_txt":" Completion: 12/24/2025","study_completion_date":" 12/24/2025","last_update_posted":"2023-01-02"},{"id":"07ab1569-8076-4047-9873-382e6164c635","acronym":"","url":"https://clinicaltrials.gov/study/NCT05601466","created_at":"2022-11-03T04:55:58.967Z","updated_at":"2024-07-02T16:36:00.901Z","phase":"Phase 1","brief_title":"Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia","source_id_and_acronym":"NCT05601466","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • QN-023a"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2022-11-07"},{"id":"6d47cf58-c1e8-40cb-9336-c3af2e42c71f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05215015","created_at":"2022-02-05T18:27:41.589Z","updated_at":"2024-07-02T16:36:17.805Z","phase":"Phase 1","brief_title":"Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05215015","lead_sponsor":"Wuxi People's Hospital","biomarkers":" IL6 • TNFA • CD33 • IL2 • IL10","pipe":" | ","alterations":" CD33 positive","tags":["IL6 • TNFA • CD33 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBR733"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 11/30/2022","study_completion_date":" 11/30/2022","last_update_posted":"2022-01-31"},{"id":"1f2d0edd-3aa3-4ee5-bf61-cd430b705bcf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03705858","created_at":"2021-01-18T18:09:32.951Z","updated_at":"2024-07-02T16:37:02.100Z","phase":"Phase 1","brief_title":"Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03705858","lead_sponsor":"Joseph Jurcic","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actimab-A (lintuzumab-Ac225) • Zamyl (lintuzumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 02/28/2019","primary_completion_date":" 02/28/2019","study_txt":" Completion: 02/28/2019","study_completion_date":" 02/28/2019","last_update_posted":"2019-03-08"},{"id":"e218cb17-cf88-493f-bf4f-8dea7254ff69","acronym":"","url":"https://clinicaltrials.gov/study/NCT01690624","created_at":"2021-01-18T07:20:15.892Z","updated_at":"2024-07-02T16:37:10.550Z","phase":"Phase 1","brief_title":"BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse","source_id_and_acronym":"NCT01690624","lead_sponsor":"Boehringer Ingelheim","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 836858"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/13/2012","start_date":" 09/13/2012","primary_txt":" Primary completion: 05/21/2018","primary_completion_date":" 05/21/2018","study_txt":" Completion: 05/21/2018","study_completion_date":" 05/21/2018","last_update_posted":"2018-05-23"}]